The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.

Here’s the latest list of major oversold players in this sector, having an RSI near or below 30.

United Therapeutics Corp (NASDAQ:UTHR)

  • On Sept. 2, the company announced the FDA acceptance of its sNDA for nebulized Tyvaso Inhalation Solution to treat idiopathic pulmonary fibrosis. Martine Rothblatt, Ph.D.,Chairperson and Chief Executive Officer of United Therapeutics said, “We’re galvanized by the FDA’s acceptance of the nebulized Tyvaso sNDA for review and believe the strength and rigor of our TETON clinical program support an approvable application for this differentiated multi-pathway treatment for patients managing this life-threatening disease.” The company’s stock fell around 4% over the past five days and has a 52-week low of $375.61.
  • RSI Value: 29.8
  • UTHR Price Action: Shares of United Therapeutics fell 4% to close at $492.02 on Wednesday.
  • Edge Stock Ratings: 46.35 Momentum score with Value at 60.30.

Collegium Pharmaceutical Inc (NASDAQ:COLL)         

  • On Aug. 13, Collegium Pharma announced a $50 million accelerated share repurchase program. The company’s stock fell around 32% over the past month and has a 52-week low of $23.84.
  • RSI Value: 28.9
  • COLL Price Action: Shares of Collegium Pharmaceutical gained 1.3% to close at $24.30 on Wednesday.
  • Benzinga Pro’s charting tool helped identify the trend in COLL stock.

Akso Health Group – ADR (NASDAQ:AHG)

  • On April 27, Akso Health Group initiated an R&D program for its proprietary brain-computer interface technology. Yilin (Linda) Wang, Chief Executive Officer of Akso Health Group, said, "This strategic initiative marks the beginning of our effort to build a new, long-term growth engine for AHG. We are investing in the foundational R&D and intellectual property we believe will be necessary to compete in the global neurotechnology market. We are committed to pursuing it rigorously and in full compliance with all applicable regulations." The company’s stock fell around 36% over the past month and has a 52-week low of $0.84.
  • RSI Value: 29
  • AHG Price Action: Shares of Akso Health fell 5.6% to close at $0.85 on Wednesday.
  • Benzinga Pro’s signals feature notified of a potential breakout in AHG shares.

BZ Edge Rankings: Find out where other stocks stand—explore the full comparison now.

Photo via Shutterstock